{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:42:44Z","timestamp":1795034564206,"version":"4.10.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study evaluated the outcomes of a bare metal stent (BMS), DCB alone, atherectomy plus a drug-coated balloon (AT\u2009+\u2009DCB) and AT alone for the treatment of femoropopliteal artery occlusion. Four groups were included in this retrospective cohort study: 119 patients underwent the BMS procedure, 89 patients underwent DCB alone, 52 patients underwent AT\u2009+\u2009DCB, and 61 patients underwent AT alone. Patients were followed-up at 1, 6, 12 and 24\u00a0months after the procedure, the clinical outcomes and complications were assessed, and the primary outcomes were primary patency and restenosis. AT\u2009+\u2009DCB showed a lower bailout stent, and BMS displayed a higher retrograde puncture, flow-limiting dissection and postdilation (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). For all procedures, the walking distance, ABI and pain score post-procedure were significantly improved compared with the pre-procedure values (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The restenosis rate was higher in BMS (21.0%) and AT alone (24.6%) than in DCB (10.1%) alone and AT\u2009+\u2009DCB (11.5%) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04); there was no difference in amputation or clinically driven target lesion revascularization among procedures. The primary patency rates were 77.7%, 89.4%, 88.0% and 73.7% in the BMS, DCB alone, AT\u2009+\u2009DCB and AT alone groups at 24\u00a0months, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03), while the secondary patency and main adverse events (stroke, MI and death) were similar. Proximal concavity, proximal target vessel diameter \u2265\u20095\u00a0mm, runoff number \u2265\u20092 and DCB use were protective factors for primary patency. Our results suggested that AT\u2009+\u2009DCB and DCB alone were associated with higher primary patency, and DCB devices (combined with\/without AT) should be the preferred choice for FP lesions.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-50511-8","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T06:02:21Z","timestamp":1704175341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of mid-outcome among bare metal stent, atherectomy with or without drug-coated balloon angioplasty for femoropopliteal arterial occlusion"],"prefix":"10.1038","volume":"14","author":[{"given":"Lin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"50511_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FGR Fowkes","year":"2013","unstructured":"Fowkes, F. G. R. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 382, 1329\u20131340 (2013).","journal-title":"Lancet"},{"issue":"12","key":"50511_CR2","first-page":"e686","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman, M. D. et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135(12), e686\u2013e725 (2017).","journal-title":"Circulation"},{"issue":"4","key":"50511_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.hlc.2017.10.014","volume":"27","author":"SM Conte","year":"2018","unstructured":"Conte, S. M. & Vale, P. R. Peripheral arterial disease. Heart Lung Circ. 27(4), 427\u2013432 (2018).","journal-title":"Heart Lung Circ."},{"key":"50511_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jvs.2019.05.034","volume":"71","author":"A Mohapatra","year":"2020","unstructured":"Mohapatra, A. et al. Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries. J. Vasc. Surg. 71, 560\u2013566 (2020).","journal-title":"J. Vasc. Surg."},{"key":"50511_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/1526602815626557","volume":"23","author":"K Katsanos","year":"2016","unstructured":"Katsanos, K., Spiliopoulos, S., Paraskevopoulos, I., Diamantopoulos, A. & Karnabatidis, D. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: Role of paclitaxel dose and bioavailability. J. Endovasc. Ther. 23, 356\u2013370 (2016).","journal-title":"J. Endovasc. Ther."},{"key":"50511_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/clc.23098","volume":"42","author":"A Kansal","year":"2019","unstructured":"Kansal, A. et al. Endovascular treatment of femoro-popliteal lesions. Clin. Cardiol. 42, 175\u2013183 (2019).","journal-title":"Clin. Cardiol."},{"key":"50511_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.005891","volume":"11","author":"PA Schneider","year":"2018","unstructured":"Schneider, P. A. et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: Long-term results of the IN.PACT SFA randomized trial. Circ. Cardiovasc. Interv. 11, e005891 (2018).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"50511_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/1526602815600156","volume":"22","author":"G Tepe","year":"2015","unstructured":"Tepe, G. et al. Drug-eluting balloon therapy for femoropopliteal occlusive disease. J. Endovasc. Ther. 22, 727\u2013733 (2015).","journal-title":"J. Endovasc. Ther."},{"key":"50511_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s00270-020-02452-2","volume":"43","author":"S Mietz","year":"2020","unstructured":"Mietz, S., Lehmann, T. & Teichgraber, U. Multivariable regression analysis of clinical data from the randomized-controlled EffPac trial: Efficacy of femoropopliteal drug-coated balloon angioplasty. Cardiovasc. Interv. Radiol. 43, 840\u2013849 (2020).","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"50511_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00270-014-0904-3","volume":"37","author":"F Fanelli","year":"2014","unstructured":"Fanelli, F. et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc. Interv. Radiol. 37, 898\u2013907 (2014).","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"50511_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1024\/0301-1526\/a001010","volume":"51","author":"L Wei","year":"2022","unstructured":"Wei, L. et al. Directional atherectomy and drug-coated balloon angioplasty vs. bare nitinol stent angioplasty for femoropopliteal artery lesions. Vasa 51, 275\u2013281 (2022).","journal-title":"Vasa"},{"key":"50511_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/1708538120985732","volume":"29","author":"F Lin","year":"2021","unstructured":"Lin, F., Wang, H., Ding, W., Chen, G. & Zhang, Z. Atherectomy plus drug-coated balloon versus drug-coated balloon only for treatment of femoropopliteal artery lesions: A systematic review and meta-analysis. Vascular 29, 883\u2013896 (2021).","journal-title":"Vascular"},{"key":"50511_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1177\/1526602820952413","volume":"27","author":"K Deloose","year":"2020","unstructured":"Deloose, K. et al. Combining the Passeo-18 Lux drug-coated balloon and the pulsar-18 bare metal stent: 12- and 24-month outcomes of the BIOLUX 4EVER investigator-initiated trial. J. Endovasc. Ther. 27, 936\u2013945 (2020).","journal-title":"J. Endovasc. Ther."},{"key":"50511_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejvs.2021.02.012","volume":"62","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Atherectomy combined with balloon angioplasty versus balloon angioplasty alone for de novo femoropopliteal arterial diseases: A systematic review and meta-analysis of randomised controlled trials. Eur. J. Vasc. Endovasc. Surg. 62, 65\u201373 (2021).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"50511_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jvs.2013.02.019","volume":"58","author":"S Sixt","year":"2013","unstructured":"Sixt, S. et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J. Vasc. Surg. 58, 682\u2013686 (2013).","journal-title":"J. Vasc. Surg."},{"key":"50511_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4070\/kcj.2021.0246","volume":"52","author":"JJ Cha","year":"2022","unstructured":"Cha, J. J. et al. Clinical outcomes of atherectomy plus drug-coated balloon versus drug-coated balloon alone in the treatment of femoropopliteal artery disease. Korean Circ. J. 52, 123\u2013133 (2022).","journal-title":"Korean Circ. J."},{"key":"50511_CR17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1177\/15266028211070968","volume":"29","author":"T Zeller","year":"2022","unstructured":"Zeller, T. et al. Orbital atherectomy prior to drug-coated balloon angioplasty in calcified infrapopliteal lesions: A randomized, multicenter pilot study. J. Endovasc. Ther. 29, 874\u2013884 (2022).","journal-title":"J. Endovasc. Ther."},{"key":"50511_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/1526602820915244","volume":"27","author":"DG Kokkinidis","year":"2020","unstructured":"Kokkinidis, D. G. et al. Two-year outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of heavily calcified femoropopliteal lesions. J. Endovasc. Ther. 27, 492\u2013501 (2020).","journal-title":"J. Endovasc. Ther."},{"key":"50511_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.avsg.2020.10.051","volume":"73","author":"O Rodoplu","year":"2021","unstructured":"Rodoplu, O. et al. Efficacy of rotational atherectomy followed by drug-coated balloon angioplasty for the treatment of femoropopliteal lesions-comparison with sole drug-coated balloon revascularization: Two-year outcomes. Ann. Vasc. Surg. 73, 222\u2013233 (2021).","journal-title":"Ann. Vasc. Surg."},{"key":"50511_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.avsg.2019.06.014","volume":"64","author":"Z Cai","year":"2020","unstructured":"Cai, Z. et al. Midterm outcome of directional atherectomy combined with drug-coated balloon angioplasty versus drug-coated balloon angioplasty alone for femoropopliteal arteriosclerosis obliterans. Ann. Vasc. Surg. 64, 181\u2013187 (2020).","journal-title":"Ann. Vasc. Surg."},{"key":"50511_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.avsg.2022.10.007","volume":"90","author":"AA Kavala","year":"2023","unstructured":"Kavala, A. A., Kuserli, Y., Turkyilmaz, G., Yesiltas, M. A. & Turkyilmaz, S. Comparison of drug-coated balloon angioplasty alone and directional atherectomy combined with drug-coated balloon angioplasty in patients with lower extremity peripheral arterial disease with claudication. Ann. Vasc Surg. 90, 162\u2013171 (2023).","journal-title":"Ann. Vasc Surg."},{"key":"50511_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/1526602819855396","volume":"26","author":"EJ Armstrong","year":"2019","unstructured":"Armstrong, E. J. et al. Dissections after infrainguinal percutaneous transluminal angioplasty: A systematic review and current state of clinical evidence. J. Endovasc. Ther. 26, 479\u2013489 (2019).","journal-title":"J. Endovasc. Ther."},{"key":"50511_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.carrev.2012.03.004","volume":"13","author":"NW Shammas","year":"2012","unstructured":"Shammas, N. W. et al. Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: A retrospective review from a single center. Cardiovasc. Revasc. Med. 13, 224\u2013227 (2012).","journal-title":"Cardiovasc. Revasc. Med."},{"key":"50511_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jacc.2014.12.036","volume":"65","author":"MR Patel","year":"2015","unstructured":"Patel, M. R. et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from Peripheral Academic Research Consortium (PARC). J. Am. Coll. Cardiol. 65, 931\u2013941 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"50511_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar, J. T., Young, J. P. Jr., LaMoreaux, L., Werth, J. L. & Poole, R. M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94, 149\u2013158 (2001).","journal-title":"Pain"},{"key":"50511_CR26","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.amjcard.2007.09.017","volume":"100","author":"J Joye","year":"2007","unstructured":"Joye, J. The PATRIOT (peripheral approach to recanalization in occluded totals) study results. Am. J. Cardiol. 100, S24 (2007).","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"50511_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jvir.2022.11.021","volume":"34","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Effectiveness and safety of atherectomy versus plain balloon angioplasty for limb salvage in tibioperoneal arterial disease. J. Vasc. Interv. Radiol. 34(3), 428\u2013435 (2023).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"50511_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jvs.2022.08.020","volume":"77","author":"K Oh","year":"2023","unstructured":"Oh, K. et al. Comparison of outcomes for balloon angioplasty, atherectomy, and stenting in the treatment of infrapopliteal disease for chronic limb-threatening ischemia. J. Vasc. Surg. 77, 241\u2013247 (2023).","journal-title":"J. Vasc. Surg."},{"key":"50511_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.avsg.2018.06.015","volume":"55","author":"JW Roh","year":"2019","unstructured":"Roh, J. W. et al. Risk factors for restenosis after drug-coated balloon angioplasty for complex femoropopliteal arterial occlusive disease. Ann. Vasc. Surg. 55, 45\u201354 (2019).","journal-title":"Ann. Vasc. Surg."},{"key":"50511_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jvs.2019.01.080","volume":"70","author":"C Caradu","year":"2019","unstructured":"Caradu, C. et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J. Vasc. Surg. 70, 981-995.e10 (2019).","journal-title":"J. Vasc. Surg."},{"key":"50511_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21037\/qims.2019.11.15","volume":"10","author":"R Loffroy","year":"2020","unstructured":"Loffroy, R. et al. Percutaneous mechanical atherothrombectomy using the Rotarex\u00aeS device in peripheral artery in-stent restenosis or occlusion: A French retrospective multicenter study on 128 patients. Quant. Imaging Med. Surg. 10, 283\u2013293 (2020).","journal-title":"Quant. Imaging Med. Surg."},{"key":"50511_CR32","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s10103-021-03393-z","volume":"37","author":"S Yang","year":"2022","unstructured":"Yang, S., Li, S., Hou, L. & He, J. Excimer laser atherectomy combined with drug-coated balloon versus drug-eluting balloon angioplasty for the treatment of infrapopliteal arterial revascularization in ischemic diabetic foot: 24-month outcomes. Lasers Med. Sci. 37, 1531\u20131537 (2022).","journal-title":"Lasers Med. Sci."},{"key":"50511_CR33","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/ccd.26984","volume":"89","author":"TR Foley","year":"2017","unstructured":"Foley, T. R. et al. Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease. Catheter Cardiovasc. Interv. 89, 1078\u20131085 (2017).","journal-title":"Catheter Cardiovasc. Interv."},{"key":"50511_CR34","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1177\/17085381221098289","volume":"31","author":"T Pan","year":"2022","unstructured":"Pan, T. et al. Anemia as a risk factor for restenosis in femoropopliteal arterial disease after drug-coated balloon angioplasty. Vascular 31, 948\u2013953 (2022).","journal-title":"Vascular"},{"key":"50511_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/1526602819860124","volume":"26","author":"S Ichihashi","year":"2019","unstructured":"Ichihashi, S. et al. Vessel calcification as a risk factor for in-stent restenosis in complex femoropopliteal lesions after Zilver PTX paclitaxel-coated stent placement. J. Endovasc. Ther. 26, 613\u2013620 (2019).","journal-title":"J. Endovasc. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50511-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50511-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50511-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T06:12:17Z","timestamp":1704175937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50511-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50511"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50511-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"26 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}